Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Raises $12.5 Million in Series D Led by Schott

NEW YORK, April 15 - NimbleGen Systems of Madison, Wis., has raised an additional $12.5 million in a series D round of financing led by European technology giant Schott, the microarray company said today.


This brings the total amount that the company has raised to $32.5 million.


Schott Nexterion of Mainz, Germany, which is Schott's new life sciences division, led the financing.   ITX of Japan also participated, as did the company's existing venture capital and institutional investors: Skyline Ventures, Venture Investors, Baird Venture Partners, Tactics II Investments LLC, State of Wisconsin Investment Board, and The Wisconsin Alumni Research Foundation.


Schott, a $2 billion company that has expertise in manufacture of glass and fiber optics, has been a frequent if low-key exhibitor at recent microarray conferences, and company representatives have expressed an interest in collaborations with companies in the sector.


NimbleGen, founded in 2000, has developed technology that uses light-directed chemical synthesis to rapidly build oligo probes on high-density arrays: It boasts of being able to produce an array in a little as three hours.


  "The NimbleGen business model fits closely with Schott's strategic plan for investing in innovative microarray technology platforms, said Dirk van den Broek, Schott Nexterion CEO, in a statement. "We are building on our well-established uncoated and coated flat glass products for DNA microarrays and investing in new products and unique microarray technologies."

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.